CellREDM and Re2O in Daegu — both hADM, so what is different?
Both products place the structural material left after cells and DNA are removed from donated human skin (hADM) into the dermis. The idea is the same; what differs is particle size and whether a published human study exists. Here is why Miso Clinic stocks both and divides them by area.
The short answer
CellREDM and Re2O belong to the same hADM class and share an aim; the choice comes down to the area and the skin thickness. CellREDM has particles milled to about 75 μm to reduce injection resistance and clumping in thin areas such as around the eyes, while Re2O is used mainly on larger areas such as the cheeks and forehead. The depth of evidence differs — Re2O has a 20-person, 20-week split-face double-blind randomised trial, while we could not find any published human clinical study of CellREDM. No study compares the two directly.
What is hADM, and why start with the raw material?
hADM (human acellular dermal matrix) is the extracellular matrix — collagen, elastin, glycosaminoglycans — left after cells and DNA are removed from donated human skin. Rather than signalling the skin to make collagen, it supplies the lost material directly, and among booster classes only hADM works this way.
Much promotional material explains these products while leaving out that the raw material is human skin. Miso Clinic always tells you before treatment, and if that makes you uncomfortable we change the plan to a class that is not of human origin. hADM is not a medical device but human tissue, regulated under Korea’s Act on Safety and Management of Human Tissue.
The sentence “a material long used in burn treatment and breast reconstruction” explains what the material is, but it does not stand in as a guarantee of the effect or safety of injectable hADM.
CellREDM and Re2O: what is the same and what differs?
| Item | Re2O | CellREDM |
|---|---|---|
| Manufacturer | L&C Bio | Hans Biomed (Korean distribution rights: Hugel) |
| Particles | Varies by line-up (a separate finer line exists) | About 75 μm (manufacturer figure) |
| Main areas used (clinical judgement) | Larger areas such as cheeks and forehead | Thin, sensitive areas such as around the eyes |
| Published human study | Split-face double-blind randomised trial, 20 people · 20 weeks | Not found |
| In common | hADM class · distributed as human tissue · does not create volume |
What changes when particles are smaller? When something is injected into the dermis, the larger the particles, the greater the injection resistance; greater resistance means more pain and a tendency to pool in one spot. In thick areas that is not a problem, but where the dermis is thin, such as around the eyes, it shows. CellREDM is designed to reduce that burden.
The data cannot say which of the two is better. Miso Clinic keeps both not because one outranks the other, but because with only one product, that one ends up being used on every area.
How far does the evidence go?
Re2O has a split-face double-blind randomised trial from Severance Hospital, Yonsei University. Re2O went on one side of the face and hyaluronic acid on the other, compared over 20 weeks; because the design compares left and right in the same person, variables such as age, skin thickness and lifestyle cancel out. But 20 people over 20 weeks is exploratory in scale, with almost no power to catch rare adverse events.
We could not find any published human clinical study of CellREDM itself. So for CellREDM we do not use expressions such as “lasts so many months” or “needs so many sessions”. Nor do we transfer Re2O’s results to CellREDM — the class is the same, but the products are different.
A regulatory change is also worth noting. On 16 July 2026 the MFDS gave advance notice of an amendment to the Enforcement Rule on human tissue (Notice No. 2026-340); as of September 2026 it has not been promulgated.
Which concerns suit hADM, and which suit another class?
| Concern | Consider first | Why |
|---|---|---|
| Fine lines around the eyes · density in thin areas | CellREDM | Fine particles mean less injection resistance and clumping |
| Overall density and texture of cheeks and forehead | Re2O | Larger areas; a human study exists |
| Skin made reactive by repeated laser or lifting | hADM or Rejuran | Avoids the nodule burden of stimulating boosters |
| Hollow cheeks or temples | Neither | hADM does not create volume — fillers or CaHA |
| Collapsed jawline and sagging | Neither | The territory of lifting devices |
| Uncomfortable with a raw material of human origin | Another class | Plan with BYRYZN, Rejuran, GOURI or CaHA |
Summary
What is established
- Both products are hADM — a class that supplies material directly, distributed as human tissue
- CellREDM particles about 75 μm (manufacturer figure)
- Re2O split-face double-blind randomised trial, 20 people · 20 weeks (control: hyaluronic acid)
What we could not find
- A published human clinical study of CellREDM itself
- A direct comparison of CellREDM and Re2O
- Long-term duration and a standard number of sessions for either product
CellREDM and Re2O in Daegu: frequently asked questions
Which is better, CellREDM or Re2O?
There are no clinical data comparing the two products directly, so there is no basis for ranking them. They belong to the same hADM class, and we divide them by area and skin thickness: CellREDM, with its finer particles, first for thin areas such as around the eyes, Re2O first for larger areas.
These are made from human skin. Is that all right?
It is true that the raw material is donated human skin; cells and DNA are removed and only the structural components are used. Donated tissue goes through infection screening and the tissue bank management system. If it still bothers you, a quite different plan using classes not of human origin is entirely possible.
Can CellREDM be used around the eyes?
CellREDM’s fine particles are formulated with thin areas such as around the eyes in mind, but whether it is suitable is judged by examining your skin thickness and condition directly. Depending on the area, another class can be the better choice.
Do Re2O’s study results apply to CellREDM?
We do not transfer them. Even within the same class, the products differ in processing and particles, so the Re2O split-face trial does not vouch for CellREDM’s results.
How many hADM sessions do I need?
There is no research-established standard number. Miso Clinic reviews progress after one session and decides together with you whether to add more; we do not recommend a bundle of sessions from the start.
Read next
- CellREDM reference — the same hADM idea, ground finer
- Re2O reference — an hADM skin booster
- hADM (Re2O · CellREDM): how far has this material been established?
- Lines around and under the eyes in Daegu — treatments to use and to avoid
- BYRYZN, Rejuran or Re2O — choosing among three skin boosters in Daegu
Product pages
Each product is covered in the CellREDM reference · Re2O reference.
Who wrote this
Written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu, South Korea. Every study cited above is given together with its design, its size and the limitations the authors themselves recorded, and where we could not find data, we have said that we could not find any.
| Medical director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Phone | +82-53-428-2700 |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Columns | All clinical columns |
| Reference library | All booster and device references |
References
- Re2O split-face trial — Severance Hospital, Yonsei University; split-face, double-blind randomised trial (NCT07155278), International Journal of Molecular Sciences 2026. 20 subjects · 20 weeks · Re2O on one side, hyaluronic acid on the other. Exploratory in scale.
- CellREDM product information — manufactured by Hans Biomed (Korean distribution rights: Hugel). hADM microparticles of about 75 μm (manufacturer figure). We could not find any published human clinical study of CellREDM itself.
- Human tissue regulation — Korea’s Act on Safety and Management of Human Tissue (tissue bank licensing, Article 13; import, Article 17). On 16 July 2026 the MFDS gave advance notice of an amendment to the Enforcement Rule (Notice No. 2026-340); not promulgated as of September 2026.
- Miso Clinic clinical protocols — criteria for indications, design by area, and the explanation and consent process before treatment. The source of the sentences marked “clinical judgement” in this column.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.